Stewart D. Chipman

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.